End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3,917 MXN | -3.26% | -3.26% | +0.20% |
13/06 | Baird Adjusts Price Target on Charles River Laboratories International to $271 From $270 | MT |
07/06 | The job report just threw a spanner in the works |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With a 2024 P/E ratio at 26.34 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.20% | 1.08TCr | - | ||
+40.80% | 5.37TCr | B- | ||
+35.79% | 3.89TCr | A | ||
-8.05% | 3.88TCr | B | ||
-8.98% | 2.73TCr | C | ||
+10.69% | 2.59TCr | B- | ||
-16.21% | 2.03TCr | B | ||
+31.00% | 1.28TCr | B+ | ||
+28.51% | 1.22TCr | C+ | ||
-1.67% | 1.2TCr | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CRL Stock
- CRL * Stock
- Ratings Charles River Laboratories International, Inc.